CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric Oxygen for Radiation Cystitis, A Controlled Study
John J. Feldmeier DO 1, John P. Kirby MD 2, Helen B. Gelly MD3 Marc Robins DO 4, John Peters FACHE 5 Peter Gruhn, MA6, Sarmistha Pal, PhD6
1. Professor Emeritus and Past Chairman, Radiation Oncology, University of Toledo Medical Center.
2. Associate Professor of Surgery, Washington University School of Medicine in St Louis, MO
3. President, Regenerative and Hyperbaric Medicine, Marietta, Georgia
4. Marc Robins, DO, MPH, FUHM, FAACP
5. John S. Peters, FACHE, ED UHMS
6. Peter Gruhn, M.A., Dobson DaVanzo and Associates, LLC
6. Sarmistha Pal, Ph.D., Dobson DaVanzo and Associates, LLC
Key Words: controlled study; cost-effectiveness; clinical effectiveness; hyperbaric oxygen; radiation cystitis
Running Title: Hyperbaric Oxygen for Radiation Cystitis
Acknowledgments:
1. The Project was supported by an unrestricted grant from Healogics, LLC
2. The authors also wish to express their thanks to the following individuals for input and editorial review:
a. Joan E. DaVanzo, Ph.D., M.S.W., Chief Executive Officer Dobson DaVanzo and Associates, LLC (deceased)
b. John A. Gelly, MD, Retired Physician, Marietta, GA
c. Costantino Balestra Ph.D., Professor of Physiology, Vrije Universiteit Brussel (V.U.B.) VP. Research & Education DAN Europe
d. Renee Duncan, BA, UHMS Consulting Copy Editor
CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric ..